Leal Health, formerly known as Trialjectory, presented data on the negative impact of Eastern Cooperative Oncology Group, or ECOG, performance status scores on cancer patients’ eligibility to enroll in clinical trials at the American Society of Clinical Oncology Genitourinary Cancers Symposium.
Exploratory analyses of the POTOMAC phase III trial showed adding one year of treatment with AstraZeneca’s Imfinzi (durvalumab) to BCG induction and maintenance therapy reduced the number of high-risk disease recurrences within the first year, with fewer BCG-unresponsive recurrences in patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer compared to BCG treatment alone.
